Berberine sulfate (Berberal) is a quaternary ammonium salt of the benzylisoquinoline alkaloid proto-berberines, which can be used in the study of type 2 diabetes mellitus, abdominal obesity and metabolism-related fatty liver disease.

Berberine sulfate (1.25-160 μM; 72 h) has a potential inhibitory effect on the proliferation of four colorectal cancer cell lines, LoVo, HCT116, SW480, and HT-29.[5]
Berberine suLfate (1.25-160 μM; 24-72 h) induces time- and dose-dependent inhibition of LoVo cell growth.[5]
LoVo cells were exposed to Berberine sulfate (10 -80 μM) for 24 hours. Cell cycle analysis of LoVo cells treated with 40 μM berberine by flow cytometry showed an accumulation of cells in the G2/M phase.[5]
Berberine sulfate (10 -80 μM) inhibits the expression of cyclin B1, cdc2, and cdc25c proteins after 24 hours, especially at the dose of 80.0 μM.[5]

Berberine sulfate (10, 30, or 50 mg/kg/day; gastrointestinal gavage; 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine (30 and 50 mg/kg/d; gastrointestinal gavage) inhibited the growth of human colorectal adenocarcinoma xenografts in nude mice by 33.1% and 45.3%, respectively.[5]